ELUT
BULLISH
$1.14
Live
Elutia Inc. · NASDAQ
Target $5.0
(+338.6%)
$0.5
52W Range
$2.64
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 09, 2026
Market cap
$48.77M
P/E
N/A
ROE
N/A
Profit margin
434.2%
Debt/Equity
0.14
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
ELUT shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 0/9). Key strengths include strong valuation and growth metrics.
Key Strengths
Strong profitability (434.2% margin)
Strong revenue growth of 16.2%
Low debt with D/E ratio of 0.14
Key Risks
Weak financial trend (Piotroski F-Score: 0/9)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
42
Moderate
50
65
60
35
0
AI Verdict
ELUT shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 0/9). Key strengths include strong valuation and growth metrics.
Key drivers: Strong profitability (434.2% margin), Strong revenue growth of 16.2%, Weak financial trend (Piotroski F-Score: 0/9)
Confidence
65%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
65/100
Rule-based growth outlook.
Positives
- Revenue growth running at 16.2%.
Watchpoints
No urgent risks highlighted.
Past
60/100
Historical performance + price trend: Shares moved -91.4% over 5Y and -53.7% over 1Y.
Positives
- Healthy profit margin of 434.2%.
Watchpoints
No urgent risks highlighted.
Health
35/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Low D/E ratio (0.14).
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.14
Analyst Target
$5.0
Upside/Downside
+338.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ELUT and closest competitors.
Updated 2026-04-08
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ELUT
Elutia Inc.
Primary
|
-91.4% | -20.8% | -53.7% | +28.2% | -2.6% | +4.6% |
|
ALGS
Aligos Therapeutics, Inc.
Peer
|
-98.8% | -77.7% | -26.4% | -25.8% | +1.5% | +8.4% |
|
ARAY
Accuray Incorporated
Peer
|
-93.2% | -87.0% | -78.7% | -76.4% | -27.4% | -24.4% |
|
APLM
Apollomics, Inc.
Peer
|
-98.0% | -98.1% | +148.8% | +191.4% | -0.5% | -0.8% |
|
BTMD
biote Corp.
Peer
|
-85.2% | -74.7% | -54.1% | -47.5% | -16.8% | +10.4% |
ELU
Elutia Inc.
Primary
5Y
-91.4%
3Y
-20.8%
1Y
-53.7%
6M
+28.2%
1M
-2.6%
1W
+4.6%
ALG
Aligos Therapeutics, Inc.
Peer
5Y
-98.8%
3Y
-77.7%
1Y
-26.4%
6M
-25.8%
1M
+1.5%
1W
+8.4%
ARA
Accuray Incorporated
Peer
5Y
-93.2%
3Y
-87.0%
1Y
-78.7%
6M
-76.4%
1M
-27.4%
1W
-24.4%
APL
Apollomics, Inc.
Peer
5Y
-98.0%
3Y
-98.1%
1Y
+148.8%
6M
+191.4%
1M
-0.5%
1W
-0.8%
BTM
biote Corp.
Peer
5Y
-85.2%
3Y
-74.7%
1Y
-54.1%
6M
-47.5%
1M
-16.8%
1W
+10.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.04
PEG Ratio
N/A
P/B Ratio
1.76
P/S Ratio
3.97
EV/Revenue
1.33
EV/EBITDA
-0.95
Market Cap
$48.77M
Profitability
Profit margins and return metrics
Profit Margin
434.23%
Operating Margin
-167.87%
Gross Margin
53.66%
ROE
N/A
ROA
-23.37%
Growth
Revenue and earnings growth rates
Revenue Growth
+16.2%
Earnings Growth
N/A
Q/Q Revenue Growth
-40.18%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.14
Low debt
Current Ratio
2.22
Strong
Quick Ratio
1.51
Excellent
Cash/Share
$0.85
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
58.5%
Op. Margin
-167.9%
Net Margin
2164.2%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
1.25x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
103%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-11
$1.48
+1157.1% surprise
2025-11-06
$-0.09
+41.9% surprise
2025-08-14
$-0.23
-35.3% surprise
Healthcare Sector Comparison
Comparing ELUT against 189 companies in the Healthcare sector
(17 bullish, 63 neutral, 109 bearish)
Profit Margin
434.23%
This Stock
vs
-19.57%
Sector Avg
-2319.2%
(Weaker)
Debt to Equity
0.14
This Stock
vs
5.1
Sector Avg
-97.2%
(Less Debt)
Revenue Growth
16.2%
This Stock
vs
108.17%
Sector Avg
-85.0%
(Slower)
Current Ratio
2.22
This Stock
vs
3.39
Sector Avg
-34.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ELUT
Elutia Inc.
|
BULLISH | $48.77M | - | -% | 434.2% | $1.14 | |
|
ALGS
Aligos Therapeutics, Inc.
|
BEARISH | $46.58M | - | -196.9% | -% | $7.57 | Compare |
|
ARAY
Accuray Incorporated
|
BEARISH | $44.0M | - | -70.3% | -8.2% | $0.37 | Compare |
|
APLM
Apollomics, Inc.
|
BEARISH | $42.65M | - | -380.1% | -% | $19.9 | Compare |
|
BTMD
biote Corp.
|
NEUTRAL | $55.53M | 2.01 | -% | 14.1% | $1.49 | Compare |
ELUT
Elutia Inc.
BULLISH
Mkt Cap
$49M
P/E
-
ROE
-%
Price
$1.14
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-10 | MILLS CHARLES RANDAL | Chief Executive Officer | Stock Award | 27,084 | - |
| 2026-03-10 | FERGUSON MATTHEW B | Chief Financial Officer | Stock Award | 12,500 | - |
| 2026-03-10 | WILLIAMS MICHELLE LEROUX | Officer | Stock Award | 12,500 | - |
| 2026-01-30 | NEELS GUIDO J | Director | Purchase | 20,000 | $20,800 |
| 2026-01-30 | RAKIN KEVIN L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | 70,000 | $74,200 |
| 2026-01-29 | NEELS GUIDO J | Director | Purchase | 30,000 | $31,800 |
| 2025-12-17 | COLPMAN DAVID | Director | Purchase | 12,500 | $6,375 |
| 2025-12-17 | MAKES BRIGID A | Director | Purchase | 25,000 | $13,000 |
| 2025-12-17 | RAKIN KEVIN L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | 50,000 | $25,995 |
| 2025-12-17 | MILLS CHARLES RANDAL | Chief Executive Officer | Purchase | 3,000 | $1,530 |
| 2025-12-17 | FERGUSON MATTHEW B | Chief Financial Officer | Purchase | 60,000 | $31,800 |
| 2025-12-10 | MILLS CHARLES RANDAL | Chief Executive Officer | Stock Award | 27,083 | - |
| 2025-12-10 | FERGUSON MATTHEW B | Chief Financial Officer | Stock Award | 12,500 | - |
| 2025-12-10 | WILLIAMS MICHELLE LEROUX | Officer | Stock Award | 12,500 | - |
| 2025-12-02 | FERGUSON MATTHEW B | Chief Financial Officer | Purchase | 10,000 | $6,610 |
MILLS CHARLES RANDAL
Chief Executive Officer
2026-03-10
27,084 shares
FERGUSON MATTHEW B
Chief Financial Officer
2026-03-10
12,500 shares
WILLIAMS MICHELLE LEROUX
Officer
2026-03-10
12,500 shares
NEELS GUIDO J
Director
2026-01-30
20,000 shares
·
$20,800
RAKIN KEVIN L
Director and Beneficial Owner of more than 10% of a Class of Security
2026-01-30
70,000 shares
·
$74,200
NEELS GUIDO J
Director
2026-01-29
30,000 shares
·
$31,800
COLPMAN DAVID
Director
2025-12-17
12,500 shares
·
$6,375
MAKES BRIGID A
Director
2025-12-17
25,000 shares
·
$13,000
RAKIN KEVIN L
Director and Beneficial Owner of more than 10% of a Class of Security
2025-12-17
50,000 shares
·
$25,995
MILLS CHARLES RANDAL
Chief Executive Officer
2025-12-17
3,000 shares
·
$1,530
FERGUSON MATTHEW B
Chief Financial Officer
2025-12-17
60,000 shares
·
$31,800
MILLS CHARLES RANDAL
Chief Executive Officer
2025-12-10
27,083 shares
FERGUSON MATTHEW B
Chief Financial Officer
2025-12-10
12,500 shares
WILLIAMS MICHELLE LEROUX
Officer
2025-12-10
12,500 shares
FERGUSON MATTHEW B
Chief Financial Officer
2025-12-02
10,000 shares
·
$6,610
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning ELUT from our newsroom.
Newest → oldest
No matching news yet.